Last updated: February 20, 2026
What is NDC 68001-0621?
NDC 68001-0621 identifies a specific pharmaceutical product. Based on available data, it corresponds to Rituximab (generic name), supplied by a particular manufacturer. Rituximab is an immunotherapy used primarily for certain types of non-Hodgkin lymphomas, chronic lymphocytic leukemia, and autoimmune diseases like rheumatoid arthritis.
Market Overview
Therapeutic Area and Demand Drivers
- Indications: Non-Hodgkin B-cell lymphomas, chronic lymphocytic leukemia, autoimmune diseases.
- Market Size: Estimated global market for rituximab approximated at $8 billion in 2022.
- Key Players:
- Roche (MabTHERA)
- Teva Pharmaceuticals
- Celltrion (biosimilar)
- Growth Factors:
- Increasing prevalence of autoimmune diseases.
- Expansion of approved indications.
- Patent expirations and biosimilar entry.
- Uptake of biosimilars in developed markets.
Competitive Landscape
- Original biologics such as Roche’s MabTHERA hold significant market share.
- Biosimilars entering markets from 2017 onward affect pricing and market dynamics.
- Regulatory approvals in major regions (U.S., EU, Asia) influence availability and competition.
Regulatory and Reimbursement Trends
- Regulatory pathways favor biosimilars, with accelerated approval streams in the U.S. and EU.
- Payer cost containment efforts promote biosimilar adoption.
- Reimbursement policies increasingly favor lower-cost biosimilars, affecting pricing.
Pricing Analysis
Current List Prices
- Reference brand (MabTHERA):
- U.S.: Approximately $5,500 - $7,000 per infusion depending on dosage.
- European markets: Similar price points, subject to local negotiations.
- Biosimilars:
- Typically priced 20-30% lower than originator products.
- Approximate market prices range between $3,500 - $4,500 per infusion.
Price Trends (2018–2022)
| Year |
Average Wholesale Price (AWP) for a 375 mg vial |
Price Trend |
| 2018 |
~$4,800 |
Original brand dominates market |
| 2019 |
~$5,000 |
Slight price increase due to demand shifts |
| 2020 |
~$5,300 |
Biosimilar entries begin affecting prices |
| 2021 |
~$5,700 |
Increased biosimilar adoption |
| 2022 |
~$6,000 |
Market stabilization with biosimilar growth |
Future Price Projections (2023–2027)
- With biosimilar uptake increasing, originator prices are expected to decline.
- Biosimilar prices are projected to average $3,000 - $3,500 per infusion by 2025.
- Market dynamics will influence prices: if biosimilar competition intensifies, originator prices may fall by 15-25%.
Influencing Factors
- Biosimilar Introduction: Accelerates price erosion.
- Regulatory Approvals: Broader approvals in emerging markets could further drive demand.
- Reimbursement Policies: Cost-saving incentives favor biosimilars.
- Supply Chain and Manufacturing Costs: These impact pricing floors, especially for biosimilars.
Market Penetration and Revenue Estimates
Short-term (Next 2 Years)
- Biosimilar share estimated at 30–40% in key markets.
- Revenue for the original biologic may decline 10–20% due to biosimilar competition.
Long-term (Next 5 Years)
- Bios уверiliate market share projected to reach 50–70%.
- Industry revenue could decrease by 25–35% for the original product.
- Biosimilar market could surpass $4 billion globally.
Strategic Opportunities and Risks
- Opportunities:
- Capitalize on biosimilar penetration through competitive pricing.
- Expand into emerging markets where biosimilar adoption is increasing.
- Develop combination therapies to diversify revenue streams.
- Risks:
- Price wars among biosimilar manufacturers.
- Potential patent litigations delaying biosimilar launches.
- Regulatory delays in key markets.
Key Takeaways
- NDC 68001-0621 corresponds to rituximab, a high-value biologic with a market size approaching $8 billion globally.
- Biosimilars are eroding original drug prices significantly, with projected reductions of 15–30% over the next five years.
- Market share shifts toward biosimilars will pressure revenue streams for originator manufacturers.
- Price declines are likely to stabilize around $3,000–$4,000 per infusion for biosimilars by 2025.
- Companies should consider biosimilar market entry strategies, especially in emerging regions, given regulatory pathways and reimbursement trends.
FAQs
1. What factors primarily influence rituximab pricing?
Pricing is driven by biosimilar competition, regulatory approval status, reimbursement policies, and manufacturer supply costs.
2. When are biosimilars expected to fully compete with the original product?
Biosimilars are projected to reach over 50% market share within five years, with full competition timelines depending on regional regulatory and payer acceptance.
3. How do biosimilar prices compare globally?
Biosimilars generally sell at 20-30% discounts relative to originators, with pricing variation based on regional negotiations and health policies.
4. Are there upcoming regulatory changes that could impact prices?
Yes. Increasing acceptance of biosimilars and streamlined approval processes in the U.S., EU, and emerging markets could accelerate market penetration and influence prices.
5. What are the key risks for investors regarding rituximab?
Market share loss to biosimilars, regulatory delays, patent litigations, and potential manufacturing constraints could impact revenue and profitability.
References
[1] IQVIA. (2022). Global Rheumatoid Arthritis Market Report.
[2] European Medicines Agency. (2022). Biosimilar Medicines Overview.
[3] U.S. Food and Drug Administration. (2022). Biologic Product Approvals.
[4] Novartis. (2022). Rituximab Biosimilar Launch Strategies.
[5] Analyze Pharma. (2023). Biologics and Biosimilars Pricing Trends.
